SPECT/CT image-based dosimetry for Yttrium-90 radionuclide therapy: Application to treatment response.

This work demonstrates the efficacy of voxel-based 90 Y microsphere dosimetry utilizing post-therapy SPECT/CT imaging and applies it to the prediction of treatment response for the management of patients with hepatocellular carcinoma (HCC). A 90 Y microsphere dosimetry navigator (RapidSphere) within a commercial platform (Velocity, Varian Medical Systems) was demonstrated for three microsphere cases that were imaged using optimized bremsstrahlung SPECT/CT. For each case, the 90 Y SPECT/CT was registered to follow-up diagnostic MR/CT using deformable image registration. The voxel-based dose distribution was computed using the local deposition method with known injected activity. The system allowed the visualization of the isodose distributions on any of the registered image datasets and the calculation of dose-volume histograms (DVHs). The dosimetric analysis illustrated high local doses that are characteristic of blood-flow directed brachytherapy. In the first case, the HCC mass demonstrated a complete response to treatment indicated by a necrotic region in follow-up MR imaging. This result was dosimetrically predicted since the gross tumor volume (GTV) was well covered by the prescription isodose volume (V150 Gy = 85%). The second case illustrated a partial response to treatment which was characterized by incomplete necrosis of an HCC mass and a remaining area of solid enhancement in follow-up MR imaging. This result was predicted by dosimetric analysis because the GTV demonstrated incomplete coverage by the prescription isodose volume (V470 Gy = 18%). The third case demonstrated extrahepatic activity. The dosimetry indicated that the prescription (125 Gy) isodose region extended outside of the liver into the duodenum (178 Gy maximum dose). This was predictive of toxicity as the patient later developed a duodenal ulcer. The ability to predict outcomes and complications using deformable image registration, calculated isodose distributions, and DVHs, points to the clinical utility of patient-specific dose calculations for 90 Y radioembolization treatment planning.

Dysregulated heme oxygenase-ferritin system in pterygium pathogenesis.

PURPOSE: Cyclooxygenase (COX)-, lipoxygenase (LOX)-, and cytochrome P450 monooxygenase (CYP)-derived eicosanoids have been implicated in ocular surface inflammation and neovascularization. These eicosanoids are subjected to regulation by enzymes, such as heme oxygenases (HOs) and ferritin. METHODS: Quantitative polymerase chain reaction and lipidomics based on liquid chromatography-tandem mass spectrometry were performed on pterygia from patients undergoing surgical pterygium excision. Control tissues consisted of donor corneas. In addition, lipidomics based on liquid chromatography-tandem mass spectrometry was performed on tears collected from patients before the surgery. RESULTS: Messenger RNA (mRNA) expression of HO-2, the constitutive HO isoform, was upregulated by 40% in pterygia compared with control tissue, whereas the mRNA level of the inducible form, HO-1, was downregulated by more than 50%. Levels of CYP4B1 mRNA showed an approximate 2-fold increase in pterygia compared with control. Lipidomic analysis of tissues indicated a moderate elevation in Prostaglandin E2 and thromboxane B2 levels in pterygia compared with control. Among the LOX-derived metabolites, the antiinflammatory-hydroxyeicosatetraenoic acid (15-HETE) levels were significantly reduced in pterygia (79.3 ± 48.11 pg/mg protein) compared with control (586.2 ± 213.5 pg/mg protein), whereas the proinflammatory LOX- and CYP4B1-derived 12-HETE levels were 10-fold higher in pterygia (2768 ± 832.3 pg/mg protein) compared with control (231.4 ± 87.35 pg/mg protein). Prostaglandin E2 and HETEs were also present in tears from patients with pterygium but were not detected in tears from healthy volunteers. The mRNA expression levels of both light and heavy chain ferritin were 60% and 30% lower, respectively, in pterygia compared with control. CONCLUSIONS: We believe that a dysfunctional HO-ferritin system leads to increased levels of proinflammatory mediators, thus contributing to the inflammation characteristic of pterygia.

Treatment efficiency of volumetric modulated arc therapy in comparison with intensity-modulated radiotherapy in the treatment of prostate cancer.

PURPOSE: Treatment with intensity-modulated radiation therapy (IMRT) is increasingly standard for prostate cancer. Volume-modulated arc therapy (VMAT) to deliver IMRT potentially enables shorter treatment time. The aim of this study was to test this hypothesis by measuring the average patient in-room time with VMAT versus dynamic multileaf collimator (DMLC) IMRT. METHODS: Custom institutional software (RTMetrix) was used to mine the treatment times from the record-and-verify database. The in-room time (the time between patient entry and exit) was computed for each patient using RTMetrix. Average room time was compared between VMAT patients (n = 44) and IMRT patients (n = 99). Subgroup comparisons (1-arc or 2-arc VMAT, 5-field or 7-field IMRT, and electromagnetic transponder [Calypso] or gold-marker tracking) were performed. For all comparisons, 2-tailed, 2-sample, equal variance Student's t-tests were used. RESULTS: Average room time was significantly shorter for all VMAT versus DMLC IMRT (P = .0014) procedures, along with VMAT versus 7-field DMLC IMRT (P < .001), but not VMAT versus 5-field DMLC IMRT (P = .81). Room time was longer for Calypso versus gold seed patients (P < .001), but VMAT reduced treatment time in Calypso patients (P = .01). This resulted in Calypso VMAT patients' having similar treatment times to non-Calypso DMLC IMRT patients (P = .220). CONCLUSIONS: These data show that VMAT can shorten room times and improve patient throughput over 7-field DMLC IMRT. Additionally, the data demonstrate that treatment with VMAT permits the use of advanced prostate tracking (Calypso), resulting in similar room times as with standard 7-field DMLC IMRT with conventional tracking.

Quantitative analysis of pre- and post-treatment PET-CT scans using deformable image registration methods.

BACKGROUND AND PURPOSE: To investigate the utility of quantitative PET analysis for early prediction of local control following stereotactic body radiation therapy (SBRT). MATERIAL AND METHODS: An initial test cohort of fourteen cases and a validation cohort of twenty-three cases were analyzed. All patients had metastatic or recurrent cancer and underwent PET-CTs pre- and post- SBRT to a variety of sites. Local failure was defined as biopsy proven persistent/recurrent disease or progressive disease on radiologic imaging. Using deformable registration, radiation dose was transferred to the PET-CTs. Using the prescription isodose as the volume of interest (VOI), response was assessed by generating metabolic volume histograms (MVH). MVH curves examine metabolic heterogeneity in the VOI. Exploratory analyses of the test cohort evaluated the viability of multiple iso-SUV and iso-volumetric points selected from the MVH curves to serve as novel markers of response. Standard PET response markers (maximum/mean SUV and qualitative analysis) were also assessed. RESULTS: In the initial cohort, ten of fourteen patients achieved local control at last follow-up, a median of 225 days following post-SBRT PET. Three out of four local failures had an increase in max SUV, while all patients who achieved local control had a reduction in max SUV (p=0.01). Exploratory analyses using multiple iso-SUV and iso-volumetric points did not yield any factors associated with local control (p>0.05). In the validation cohort, lower post- treatment max SUV (p=.03) and reduction in max SUV (p<0.05) were significantly associated with local control. CONCLUSIONS: Reduction in max SUV following SBRT is associated with local control.

A complement receptor C5a antagonist regulates epithelial to mesenchymal transition and crystallin expression after lens cataract surgery in mice.

PURPOSE: To evaluate the effects of complement employing a mouse model for secondary cataract. METHODS: The role of complement receptor C5a (CD88) was evaluated after cataract surgery in mice. An antagonist specific to C5a receptor was administered intraperitoneally to mice. Epithelial to mesenchymal transition (EMT) was evaluated by alpha-smooth muscle actin (α-SMA) staining and proliferation by bromodeoxyuridine (5-bromo-2'-deoxyuridine, BrdU) incorporation. Gene expression patterns was examined by microarray analysis and quantitative polymerase chain reaction (QPCR). RESULTS: We found that administration of a C5aR antagonist in C57BL/6J mice decreases EMT, as evidenced by α-SMA expression, and cell proliferation. Gene expression by microarray analysis reveals discreet steps of gene regulation in the two major stages that of EMT and lens fiber differentiation in vivo. A hallmark of the microarray analysis is that the antagonist seems to be a novel stage-specific regulator of crystallin genes. At week two, which is marked by lens fiber differentiation genes encoding 12 crystallins and 3 lens-specific structural proteins were severely down-regulated. CONCLUSIONS: These results suggest a possible therapeutic role of an antagonist to C5aR in preventing secondary cataracts after surgery. Also these results suggest that crystallin gene expression can be regulated by pro-inflammatory events in the eye.

In vivo assay of folate receptors in nonfunctional pituitary adenomas with 99mTc-folate SPECT/CT.

UNLABELLED: The objective of this study was to evaluate the in vivo assay of folate receptors in nonfunctional pituitary adenomas using preoperative (99m)Tc-folate SPECT/CT and Western blot analysis (WBA) of surgical specimens as the standard. METHODS: Fifty-six patients (29 men, 27 women; age range, 29-82 y) with clinically nonfunctional pituitary adenomas on MRI underwent preoperative imaging using 666 MBq (18 mCi) of (99m)Tc-folate. SPECT/CT images and whole-body and lateral head planar images were acquired approximately 2 h after injection. Surgical resection took place within a week. WBA on a portion of the excised specimens assessed folate receptor expression in 49 patients. Attenuation-corrected (99m)Tc-folate SPECT/CT images were assessed qualitatively and quantitatively (maximal adenoma counts to background), with WBA as a standard. RESULTS: Integrated CT was useful for uptake localization and assisted region-of-interest placement. Qualitative interpretation of planar imaging yielded a sensitivity of 81% and specificity of 72%. Qualitative SPECT/CT yielded a sensitivity of 94% and specificity of 61%. Receiver-operating-characteristic curve analysis of quantitative uptake yielded a tumor-to-background cutoff ratio of 3.5, with a sensitivity of 81% and specificity of 83%. Scalp uptake yielded consistent results (over the brain, neck, and choroid plexus) for background when SPECT/CT misalignment artifacts were avoided. Detection of pituitary uptake on anterior-posterior and lateral images was hampered by facial uptake, which varied between patients. CONCLUSION: SPECT/CT of (99m)Tc-folate is an accurate method of assaying folate receptors in vivo and may provide a quantitative marker for identifying folate receptor-positive tumors. This method may also prove beneficial in selecting patients for folate-targeted therapy of clinically nonfunctional pituitary adenomas, for which there is currently no medical therapy.

PET lesion segmentation using automated iso-intensity contouring in head and neck cancer.

To improve the objectivity of the integration of positron emission tomography (PET), we used the conformality index (CI) to measure the goodness of fit of a given PET iso-SUV (standardized uptake value) level with the GTV defined on PET (GTV(PET)) and CT (GTV(CT)). Twenty-two datasets involving 20 head and neck cancer patients were identified. GTV(PET) and GTV(CT) were delineated manually.An iso-intensity method was developed to automatically segment GTV(PET-ISO) using (a) SUV and (b) maximum intensity thresholding (% Max), over a range of intensities. For each intensity, GTV(PET-ISO) was compared to GTV(PET) using the conformality index CI(PET) (and, similarly, to GTV(CT) using CICT). Comparing GTV(PET) to GTV(PET-ISO) vs comparing GTV(CT) to GTV(PET-ISO), the average peak CI was 0.68 +/- 0.09 vs 0.49 +/- 0.12 (p < 0.001), the optimum iso-SUV was 2.7 +/- 0.7 vs 2.9 +/- 1.0 (p=0. 253), and the % Max SUV was 21.8% +/- 7.6% vs 23.8% +/- 8.6% (p=0. 310), respectively. The radiation oncologist's volumes corresponded to a lower iso-SUV (3.02 +/- 0.58 vs 4.36 +/- 0.77, p< 0.001) and lower % Max SUV (24.1 +/- 9.1% vs 34.3 +/- 11.2%, p<0.001) than those drawn by the nuclear medicine physician. Though manual editing may still be necessary, PET iso-contouring is one method to improve the objectivity of GTV definition in head and neck cancer patients. Iso-SUV's can also be used to study the differences between PET's role as a nuclear medicine diagnostic test versus a radiation oncology treatment planning tool.

Pelvic shape and prostate motion: implications for target volume design and analysis of acute toxicity.

OBJECTIVES: To study the impact of pelvic shape on prostate motion and the implications for radiotherapy target design and treatment outcomes. METHODS: A total of 3741 measurements (daily shift moves in the 3 principal directions) on 29 consecutive prostate cancer patients were reviewed. All patients had 3 prostatic fiducials placed and were tracked using kilovoltage on-board imaging. Pelvic shape was categorized into android (n = 21; 2580 measurements) and gynecoid (n = 8; 1161 measurements) (defined geometrically by postoutlet to preoutlet ratio). Multivariate analyses of means/standard deviations in each principal direction were performed using major demographic, disease, anatomic, and treatment factors as covariates. Toxicity rates were compared using Fisher exact test. RESULTS: On simple t test comparisons, no mean/standard deviation reached significance, although there was a nonsignificant (0.38 vs. 0.31 cm, P = 0.083) larger mean antero-posterior (AP) movement in the gynecoid group. On multivariate analyses, gynecoid shape (P = 0.032) significantly predicted for mean AP movement, and gynecoid shape (P = 0.045) significantly predicted for standard deviation of AP movement. Pelvic AP and RL dimensions also correlated with mean and standard movement along the respective axes. There were no differences between rates of acute (GI or GU) toxicity (P = 0.456) between the android and gynecoid groups. CONCLUSIONS: Treatment strategies that do not employ daily motion tracking may require wider planning target volume margins in gynecoid patients. Tracking the prostate daily, as done in our case using fiducials/on-board imaging, can counter differences in pelvic shape to produce similar treatment outcomes.

Case study of anti-1-amino-3-F-18 fluorocyclobutane-1-carboxylic acid (anti-[F-18] FACBC) to guide prostate cancer radiotherapy target design.

PURPOSE OF THE REPORT: Anti-1-amino-3-F-18 fluorocyclobutane-1-carboxylic acid (FACBC) is a novel radiotracer, which has shown some promise for use with positron emission tomography (PET)/computed tomography (CT) for visualizing prostate cancer. Here we describe a case of a prostate cancer patient who underwent radiation treatment and had an FACBC scan obtained as part of a pilot study. METHODS: We explored the potential impact of FACBC on treatment planning. We registered the FACBC acquisition with the PET/CT, which required a simple translation. Then, we did a deformable image registration of the PET/CT with the planning CT-this process allowed the FACBC-defined gross tumor volume (GTVFACBC) to be projected into the planning CT. An intensity-modulated radiotherapy (IMRT) plan (plan A) not including GTVFACBC (with final dose to 81.0 Gy) was generated, as was an IMRT plan including the GTVFACBC to a final dose of 86.4 Gy (plan B). Target coverage and normal tissue dose volume histogram (DVH) endpoints were tabulated. RESULTS: In this particular patient, bladder constraints could not be met on any plan due to anatomic limitations. However, the impact on the rectal DVH could be assessed, and inclusion of the GTVFACBC did permit rectal DVH constraints to be met in plan B while maintaining target coverage and inhomogeneity constraints. CONCLUSION: In our test case, it was feasible to use FACBC to guide IMRT, and highlights the role of deformable image registration of the PET/CT with the planning CT. These findings can guide future studies incorporating FACBC into treatment planning.

Automated data mining of a proprietary database system for physician quality improvement.

PURPOSE: Physician practice quality improvement is a subject of intense national debate. This report describes using a software data acquisition program to mine an existing, commonly used proprietary radiation oncology database to assess physician performance. METHODS AND MATERIALS: Between 2003 and 2004, a manual analysis was performed of electronic portal image (EPI) review records. Custom software was recently developed to mine the record-and-verify database and the review process of EPI at our institution. In late 2006, a report was developed that allowed for immediate review of physician completeness and speed of EPI review for any prescribed period. RESULTS: The software extracted >46,000 EPIs between 2003 and 2007, providing EPI review status and time to review by each physician. Between 2003 and 2007, the department EPI review improved from 77% to 97% (range, 85.4-100%), with a decrease in the mean time to review from 4.2 days to 2.4 days. The initial intervention in 2003 to 2004 was moderately successful in changing the EPI review patterns; it was not repeated because of the time required to perform it. However, the implementation in 2006 of the automated review tool yielded a profound change in practice. Using the software, the automated chart review required approximately 1.5 h for mining and extracting the data for the 4-year period. CONCLUSION: This study quantified the EPI review process as it evolved during a 4-year period at our institution and found that automation of data retrieval and review simplified and facilitated physician quality improvement.

Integration of databases for radiotherapy outcomes analyses.

The technical nature of radiotherapy requires different data collection strategies for outcomes reporting than those required for most other disciplines in clinical medicine. To correlate advances in radiotherapy technology with treatment outcomes, it is necessary to integrate a given radiotherapy outcomes-study database with the record-and-verify database and with the global hospital database. The authors review the recent development of each of these categories of databases from the vantage point of radiotherapy. Their goal was to integrate these 3 databases for outcomes analyses in radiotherapy at their institution; this process involved (1) the construction of an interface between the record-and-verify database and the outcomes-study database and (2) the use of a bioinformatics database linking the outcomes-study database and the global hospital database. This bioinformatics database was successfully queried in a manner that allowed streamlining data flow of relevance to radiotherapy outcomes studies. Future directions of the application of this integration are discussed.

Trilogy image-guided stereotactic radiosurgery.

Full integration of advanced imaging, noninvasive immobilization, positioning, and motion-management methods into radiosurgery have resulted in fundamental changes in therapeutic strategies and approaches that are leading us to the treatment room of the future. With the introduction of image-guided radiosurgery (IGRS) systems, such as Trilogy, physicians have for the first time a practical means of routinely identifying and treating very small lesions throughout the body. Using new imaging processes such as positron emission tomography/computed tomography (PET/CT) scans, clinics may be able to detect these lesions and then eradicate them with image-guided stereotactic radiosurgery treatments. Thus, there is promise that cancer could be turned into a chronic disease, managed through a series of checkups, and Trilogy treatments when metastatic lesions reappear.

Free breathing gated delivery (FBGD) of lung radiation therapy: analysis of factors affecting clinical patient throughput.

PURPOSE: Accurate radiation targeting and delivery within the chest and abdomen is greatly affected by the respiratory cycle. Prior methods to minimize respiratory effect include breath-hold and abdominal compression techniques; these are subject to error secondary to variable inspiration/expiration volumes, or by the nature of many cancer patients having inherently poor respiratory function. However, advanced technology called free breathing gated delivery (FBGD) allows patients to breath normally during treatment. The photon beam is on only during a particular prescribed percentage of the respiratory cycle where the target tumor volume is minimized. Consequently, by using an intermittent beam, the time required to treat a patient is increased. No previous study has described the patient throughput ramifications of FBGD. PATIENTS AND METHODS: At Emory clinic, a gated treatment delivery system was inaugurated into clinical use beginning in June 2004. As of 12/31/2004, 15 patients have completed treatment with FBGD. The majority of patients had lung cancer (n=12) with single cases of adrenal metastasis, thymoma, and atypical carcinoid. Over 900 gated treatment fields (approximately 375 treatment sessions) were reviewed on an IRB-approved retrospective protocol. Records from the record-and-verify (R&V) system were queried using automated database mining software to obtain the treatment room time, treatment field time, beam-on time (BOT), dose rate, and monitor units (MU) for each treatment. The presence or absence of a dynamic wedge was also noted, as was the prescribed percent of the respiratory cycle treated. For comparison purposes, 13 non-gated lung cancer patients (lesions were not moving with respiration) were selected from the R&V database. RESULTS: Patients receiving FBGD required significantly more time for treatment delivery. The time required for FBGD was, on average, 5.5 times greater (range 1.2-12.2) than calculated BOT without gating. Time was further increased with the use of a dynamic wedge, which occurred in 45% (28/62) of the planned fields. The use of MV imaging also increased the time for FBGD treatment sessions by more than 7.5 min on average. CONCLUSIONS: FBGD uniformly increases the time required for RT delivery, and MV imaging and dynamic wedging even more so. Even though this technology more accurately targets tumor volumes while sparing normal tissue, the patient throughput issue may deter this technology from being implemented into busy clinical practices.

A quality assurance program for the on-board imagers.

To develop a quality assurance (QA) program for the On-Board Imager (OBI) system and to summarize the results of these QA tests over extended periods from multiple institutions. Both the radiographic and cone-beam computed tomography (CBCT) mode of operation have been evaluated. The QA programs from four institutions have been combined to generate a series of tests for evaluating the performance of the On-Board Imager. The combined QA program consists of three parts: (1) safety and functionality, (2) geometry, and (3) image quality. Safety and functionality tests evaluate the functionality of safety features and the clinical operation of the entire system during the tube warm-up. Geometry QA verifies the geometric accuracy and stability of the OBI/CBCT hardware/software. Image quality QA monitors spatial resolution and contrast sensitivity of the radiographic images. Image quality QA for CBCT includes tests for Hounsfield Unit (HU) linearity, HU uniformity, spatial linearity, and scan slice geometry, in addition. All safety and functionality tests passed on a daily basis. The average accuracy of the OBI isocenter was better than 1.5 mm with a range of variation of less than 1 mm over 8 months. The average accuracy of arm positions in the mechanical geometry QA was better than 1 mm, with a range of variation of less than 1 mm over 8 months. Measurements of other geometry QA tests showed stable results within tolerance throughout the test periods. Radiographic contrast sensitivity ranged between 2.2% and 3.2% and spatial resolution ranged between 1.25 and 1.6 lp/mm. Over four months the CBCT images showed stable spatial linearity, scan slice geometry, contrast resolution (1%; <7 mm disk) and spatial resolution (>6 lp/cm). The HU linearity was within +/-40 HU for all measurements. By combining test methods from multiple institutions, we have developed a comprehensive, yet practical, set of QA tests for the OBI system. Use of the tests over extended periods show that the OBI system has reliable mechanical accuracy and stable image quality. Nevertheless, the tests have been useful in detecting performance deficits in the OBI system that needed recalibration. It is important that all tests are performed on a regular basis.

Performance evaluation of an automated image registration algorithm using an integrated kilovoltage imaging and guidance system.

Image-guided radiation therapy delivery may be used to assess the position of the tumor and anatomical structures within the body as opposed to relying on external marks. The purpose of this manuscript is to evaluate the performance of the image registration software for automatically detecting and repositioning a 3D offset of a phantom using a kilovoltage onboard imaging system. Verification tests were performed on both a geometric rigid phantom and an anthropomorphic head phantom containing a humanoid skeleton to assess the precision and accuracy of the automated positioning system. From the translation only studies, the average deviation between the detected and known offset was less than 0.75 mm for each of the three principal directions, and the shifts did not show any directional sensitivity. The results are given as the measurement with standard deviation in parentheses. The combined translations and rotations had the greatest average deviation in the lateral, longitudinal, and vertical directions. For all dimensions, the magnitude of the deviation does not appear to be correlated with the magnitude of the actual translation introduced. The On-Board Imager (OBI) system has been successfully integrated into a feasible online radiotherapy treatment guidance procedure. Evaluation of each patient's resulting automatch should be performed by therapists before each treatment session for adequate clinical oversight.

Clinical implementation and efficiency of kilovoltage image-guided radiation therapy.

This paper describes measurements of clinical efficiency and time requirements associated with image-guided radiation therapy (IGRT). In June 2004, the authors' institution installed an integrated kilovoltage (kV) imaging system attached to a medical linear accelerator for radiographic target localization. Over the past year, 242 patients have been localized with the kV radiographic imaging system for a total of 2,700 fractions. Data were analyzed by reviewing the time required for each patient's IGRT session, broken into both image acquisition and image analysis time. Average IGRT procedure time was reviewed pertaining to months, treatment sessions, disease sites, and radiation therapists. Results showed that the average IGRT procedure time was reduced from 450 to 237 seconds from June 2004 to June 2005. Further analysis revealed that each therapist showed improvement in reducing the IGRT procedure time from the first month of use to the month of June 2005. The routine use of IGRT may ultimately be performed within 3 to 4 minutes, with minimal disruption to the clinical treatment process.

Measurements of secondary neutron dose from 15 MV and 18 MV IMRT.

Secondary neutron dose-equivalents were determined for conventional and intensity modulated radiation therapy (IMRT) prostate treatments for 15 and 18 MV X-ray beams. Conventional and IMRT treatment plans were generated to deliver 45 Gy to the prostate, seminal vessicles and external and internal iliac lymph nodes. Neutron spectra were determined by unfolding measurements from a TLD-based Bonner sphere system. Treatments using 18 MV IMRT and conventional plans result in neutron ambient dose-equivalents of 687 and 112 mSv, respectively. Delivery of the 15 MV IMRT and conventional plans results in neutron ambient dose-equivalents of 327 and 52 mSv, respectively. The data illustrate that using lower photon energies for IMRT reduces the secondary neutron dose, while still achieving comparable treatment volume coverage and sparing critical normal tissue.

The electronification of the radiation oncology treatment cycle: the promises and pitfalls of a digital department.

Radiation oncology departments are becoming more complex in terms of documentation, calculation, and delivery of therapy. Automation of such processes minimizes the likelihood of human error in each, and is clearly the direction in which the discipline is heading. The patient treatment cycle should be seamlessly integrated; unfortunately this is seldom the case given the different systems involved. We describe the Emory University experience, with cautions provided based on our lessons learned.

Role of fusion in radiotherapy treatment planning.

The fusion of functional imaging to traditional imaging modalities, such as computed tomography (CT) and magnetic resonance imaging (MRI), is currently being investigated in radiotherapy treatment planning. Most studies that have been reported are in patients with lung, brain, or head and neck neoplasms. There is a potential role for either positron emission tomography (PET) or single photon emission computed tomography (SPECT) to delineate biologically active or tumor-bearing areas that otherwise would not be detected by CT or MRI. Furthermore, target volumes may be modified by using functional imaging, which can have a significant impact in the modern era of three-dimensional radiotherapy. SPECT may also be able to identify "nonfunctional" surrounding tissue and may influence radiotherapy beam arrangement.